Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers for Lutathera in Midgut Neuroendocrine Tumors
NCT03667092Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Sep 2018
- Primary completion
- May 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of lutetium Lu 177 dotatate in midgut neuroendocrine tumors, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Peptide receptor radionuclide therapy radio-induction variation of radiosensibility/reparation genes. Started Sep 2018; status: completed.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
midgut neuroendocrine tumors
Beyond the preview
Go deeper on NCT03667092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03667092.